|
Feb 18
|
|
$49.23
$49.23
-0.0%
|
LONG
|
Marty Makary
FDA Commissioner
|
Makary notes that GLP-1 shortages are ending and emphasizes that compounders should be getting APIs directly from the patent holders (Novo Nordisk and Eli Lilly) to "play by the rules." The regulatory crackdown on "grey market" compounders eliminates low-cost competition. As the FDA forces the market back toward approved products and authorized supply chains, volume and pricing power return to the IP owners. LONG as the regulatory moat is re-established. Continued supply chain constraints or political pressure on list prices. |
CNBC
FDA's Marty Makary: Everything should be over...
|
|
Feb 17
|
|
$49.37
$49.23
-0.3%
|
N/A
|
Finnhub News
|
— |
Finnhub - NVO
The European Commission Approves Novo Nordisk...
|
|
Feb 17
|
|
$49.37
$49.23
-0.3%
|
N/A
|
Finnhub News
|
— |
Finnhub - NVO
Madrigal Pharmaceuticals: What To Expect With...
|
|
Feb 14
|
|
$49.57
$49.23
-0.7%
|
SHORT
|
@unusual_whales
|
Trump: My friend, who's very successful, I told you, seriously overweight person, he takes the fat, the fat pill or the fat shot. took Ozempic. I told him it's not working for him, it didn't work. htt |
@unusual_whales
Trump: My friend, who's very successful, I to...
|
|
Feb 13
|
|
$49.57
$49.23
-0.7%
|
LONG
|
Mike Doustdar
CEO, Novo Nordisk
|
"The pill has been the centerpiece of growth for us... We today have 246,000 people on the pill... Our pill and its clinical trial has shown 16.6% weight loss. Our competitors pill has 12.4% weight loss." While Novo lags in injectable efficacy currently, they have a distinct "moat" in the oral market. The pill opens a massive Total Addressable Market (TAM) of needle-phobic patients that the competitor (Lilly) cannot serve as effectively due to lower efficacy and higher discontinuation rates (10.4% vs 3.6%). Additionally, the upcoming 7.2mg injectable dose will match the competitor's 21% weight loss, neutralizing the main disadvantage. Long NVO as a volume play. The pricing pressure is a known short-term headwind, but the oral platform provides a durable competitive advantage in 2026. Medicare volume uptake is slower than expected; pricing headwinds compress margins more than volume expands them. |
CNBC
Novo Nordisk CEO on medicare coverage, new ob...
|
|
Feb 12
|
|
$48.93
$49.23
+0.6%
|
LONG
|
Lars Fruergaard Jørgensen
Former CEO, Novo Nordisk
|
246,000 people are already on the Wegovy pill just five weeks after launch. The CEO is aggressively litigating against compounding pharmacies using unauthorized API. The shift from injection to oral delivery removes the biggest friction point for patients (needles), expanding the TAM (Total Addressable Market) significantly. Legal wins against compounders will restore pricing power and volume to the official product. Long NVO on the successful form-factor pivot. US government pressure on drug pricing. |
Bloomberg Markets
Trump Rebuked Over Canada Tariffs as Midterm ...
|
|
Feb 12
|
|
$48.93
$49.23
+0.6%
|
N/A
|
Finnhub News
|
— |
Finnhub - NVO
Bloomberg Reported Novo Nordisk To Make Wegov...
|
|
Feb 11
|
|
$48.74
$49.23
+1.0%
|
LONG
|
Jared Holz
Healthcare Equity Strategist, Mizuho
|
Holz highlights that NVO shares are back at 2024 lows while LLY has outperformed, despite both having similar duopoly status in the obesity market. The valuation gap has become "alarming." NVO's new pill (Wegovy oral) has 15x better uptake than the injection launch, and they are aggressively suing compounders (HIMS) to protect their moat. LONG NVO / SHORT LLY. Expect mean reversion as NVO resolves supply issues and flexes legal power. LLY's oral candidate could outperform; compounding pharmacies might win legal battles. |
Bloomberg Markets
Stocks Steady After Strong Jobs Data Dims Rat...
|
|
Feb 11
|
|
$48.74
$49.23
+1.0%
|
LONG
|
Lars Fruergaard Jørgensen
CEO, Novo Nordisk
|
"Novo Nordisk in North Carolina makes the pill... from the scratch. Basically, the API is made in North Carolina... Many of our peers produce and have their API come from China." This is a "Geopolitical Alpha" play. With increasing US-China tensions (e.g., Biosecure Act, tariffs), pharmaceutical companies relying on Chinese API face significant supply chain risk. NVO's fully domestic US production for the oral pill creates a safety premium that peers lack. LONG NVO as a defensive play against US-China decoupling in the pharma supply chain. Manufacturing issues at the North Carolina plant. |
Bloomberg Markets
Novo Nordisk CEO on Hims Suit, Wegovy Demand ...
|
|
Feb 11
|
|
$48.74
$49.23
+1.0%
|
LONG
|
Lars Fruergaard Jørgensen
CEO, Novo Nordisk
|
"The pill starts with zero... we have 246,000 people after five weeks... 15 times better than when we launched Wegovy injection." + "90% of the people that are coming towards the pill are new patients." The market recently sold off NVO on fears of pricing pressure ("price cuts are happening on day one"). However, the CEO's data confirms that volume growth is massive and, crucially, the oral pill is expanding the Total Addressable Market (TAM) rather than cannibalizing existing injectable revenue. The volume ramp will likely offset pricing headwinds faster than Wall Street models expect. LONG NVO as the oral pill unlocks a new demographic of patients averse to injections. Supply constraints or faster-than-expected pricing degradation. |
Bloomberg Markets
Novo Nordisk CEO on Hims Suit, Wegovy Demand ...
|
|
Feb 09
|
|
$49.37
$49.23
-0.3%
|
SHORT
|
Dr. Scott Gottlieb
Former FDA Commissioner; Board Member (Pfizer, Illumina, UnitedHealth); Partner at NEA (Venture Capital)
|
Hims & Hers (HIMS) paused sales of its copycat weight-loss pill after the FDA and Novo Nordisk (NVO) threatened action. The stock dropped ~15.8%. Novo has filed a lawsuit seeking damages and a permanent ban. Gottlieb explains that HIMS claimed to use a "liposomal" delivery system to mimic Novo's patented oral absorption technology. If true, this technically makes it an "unapproved new drug," not just a compounded copy. The FDA referred the case directly to the DOJ, which is highly unusual; typically, the FDA sends a warning letter first. A DOJ referral implies the regulator is seeking an immediate injunction or seizure of products. Novo Nordisk spent ~$1.8B acquiring the specific technology to make oral semaglutide absorbable. HIMS attempted to bypass this with a novel formulation without going through the drug approval process. HIMS could theoretically settle, though Gottlieb views them as a "bad actor" unlikely to secure partnerships with big pharma. |
CNBC
Squawk Pod: Super Bowl ads & GLP-1 competitio...
|
|
Feb 09
|
|
$49.37
$49.23
-0.3%
|
LONG
|
Dr. Scott Gottlieb
Former FDA Commissioner; Board Member (Pfizer, Illumina, UnitedHealth); Partner at NEA (Venture Capital)
|
Novo Nordisk (NVO) and Eli Lilly (LLY) retain tight control over the GLP-1 market. Novo specifically spent ~$1.8B to acquire the "SNAC" technology that allows their oral drug to survive stomach acid. The regulatory crackdown on Hims validates the "moat" around Big Pharma's IP. While compounding exists, the incumbents will only partner with "compliant" telehealth platforms (like Ro) that respect regulatory boundaries, freezing out aggressive actors like Hims. Novo's patent on the absorption technology prevents generic oral versions from working effectively without infringing IP or triggering FDA "new drug" rules. Continued compounding of the *injectable* versions (which is legally distinct from the oral pill issue). |
CNBC
Dr. Scott Gottlieb on Novo Nordisk vs. Hims &...
|
|
Feb 09
|
|
$49.37
$49.23
-0.3%
|
LONG
|
—
|
Hims & Hers announced it will pull its compounded (copycat) weight loss pill off the market following threats of legal action from Novo Nordisk and the FDA. This is a "winner takes all" dynamic. Novo Nordisk successfully defended its intellectual property, removing a cheaper competitor from the shelf. Conversely, Hims & Hers loses a major growth driver and revenue stream, leading to a repricing of the stock. Novo Nordisk is up 6.7%; Hims & Hers is down 15%. Further regulatory scrutiny on drug pricing for Novo; Hims finding alternative revenue streams. |
CNBC
5 Things To Know: February 9, 2026
|